AGENDA

University of Connecticut
Board of Trustees
Committee for Research, Entrepreneurship and Innovation
Thursday, September 15, 2022

Meeting held by Telephone:

Public Call in #: (415) 655-0002 US Toll
Access Code: 2624 720 8002

Public Access Link: https://ait.uconn.edu/bot

(A recording of the meeting will be posted on the Board website https://boardoftrustees.uconn.edu/ within seven days of the meeting.)

Call to order at 1:00 p.m.

1. Public Participation*
   * If members of the public wish to address the Committee during the Public Participation portion of the meeting, you must submit a request in writing 30 minutes prior to the start of the meeting by 12:30 p.m. to the following email address: BoardCommittees@uconn.edu. Please indicate your name, telephone number, and topic on the agenda to be discussed. Per the University By-Laws, the Board may limit public comment. As an alternative, you may also submit your comments via email which will be shared with the Committee.

ACTION ITEM:


PRESENTATION/DISCUSSION ITEMS:

3. Research Program Updates
   Dr. Pamir Alpay, Vice President for Research, Innovation, and Entrepreneurship

4. Alcohol Research Center
   Dr. Lance Bauer, Professor, Department of Psychiatry

5. Korey Stringer Institute
   Dr. Douglas Casa, Professor, Department of Kinesiology

6. Other business

7. Executive Session (as needed)

8. Adjournment

PLEASE NOTE: If you are an individual with a disability and require accommodations, please e-mail the Board of Trustees Office at boardoftrustees@uconn.edu prior to the meeting.
A Brief History of the Alcohol Research Center 1978-present

Lance Bauer, Ph.D.
Principal Investigator
July 19, 2022
Accumulated Income

P50 & P60 Awards
• 44 yrs x $1.8M/yr = $79M

Associated NIH and Other Awards over 44 yrs
• R01, R21, R03, P20, T32, U10 => $120M (estimated)

TOTAL > $200M
Educational Activity

- **NIAAA T32/National Research Service Award**
  - Supports 3-yr duration training of postdoctoral fellows
  - Continuously supported for 39 yrs
  - Graduated > 50 postdoc fellows into academic or research positions

- **Training of addiction psychiatrists, junior faculty, medical and grad students (some supported by NIH Career Development and Individual Fellowship awards)**

- **Partnerships with RCMI’s and HBCU’s**
  - U54-supported training of Latinx faculty & students at FIU
Collaborations

UConn Departments and Centers
• Anesthesiology, Medicine, Cardiology, Neuroscience, Neurology, Radiology, Population Health Sciences (formerly Comm Med), SODM, Center on Aging, CHIP, Psychology, Social Work, CRC, ....

Other Universities
• Yale, Columbia, BU, University of Alaska, VCU, FIU, UCSD, USC, Indiana U, SUNY Downstate, UMich, UIowa, Howard, Drew, Harvard, ....

International
• Japan, France, Germany, UK, Austria, Mexico, among others
Service

Grant Review Committees
• CSR, NIAAA, NIDA, NIMH, CDC, VA

Journal Editorial Positions
• Addiction, ACER, JSAD, Addictive Behavior, DAD

Policy Consultation
• WHO, NIAAA Council, NIH Council of Councils
How are we significant and innovative?

Most NIAAA-supported ARC’s focus on
• Neurobiology, epidemiology, liver disease, HIV, immunology…

We focus on
• Etiology and treatment of both children and adults with alcohol problems
Notable Previous Accomplishments

A leader in precision medicine approaches to addiction biology and treatment
  • Coordinating Center for Project MATCH
  • Collaborative Study on the Genetics of Alcoholism

A leader in pharmacotherapy development
  • Naltrexone
  • Vivitrol™
  • Acamprosate
  • Naltrexone and acamprosate are the first new meds to be approved by FDA since 1950
Notable Previous Accomplishments

A leader in alcohol problem assessment

• Screening (AUDIT) and Brief Intervention (SBIRT)
• Developed structured interviews (SSAGA) and real time assessment (ecological momentary assessment) approaches for alcohol misuse and abuse
• DSM workgroup membership
Novel Psychological and Behavioral Interventions

- Contingency Management
- Social network interventions
- Individualized coping skills training informed by pre-tx real time (IVR/EMA) assessments of drinking and reasons for drinking
Testing New Technologies in the Clinical Setting

Area #1 - Novel and objective biomarkers of alcohol use and misuse among patients in treatment

- SCRAMx
- Phosphatidylethanol

Area #2 - Genetic polymorphisms (especially GABRA2) as predictors of risk, psychosocial and pharmacological treatment outcomes, and relapse risk.

Area #3 - Implementation of CM throughout the VA Healthcare System and Medicaid clinics in CA.